Review Article
Tyrosine Kinase Inhibitors Induced Thyroid Dysfunction: A Review of Its Incidence, Pathophysiology, Clinical Relevance, and Treatment
Table 3
Frequency of reported hypothyroidism and hyperthyroidism for different tyrosine kinase inhibitors used.
| Tyrosine kinase inhibitors | Frequency of hypothyroidism | Frequency of isolated hyperthyroidism |
| Sunitinib | 53–85% | 10% | Sorafenib | 20–36% | 2.6–5% | Imatinib | 90–100% (only in patients who underwent previous thyroidectomies) | 0% | Motesanib diphosphate | 22% | 0% | Vandetanib | 89% | 0% | Axitinib | 83–92% (small number of patients in studies included) | 16% | Pazopanib | 10–29% | 0% | Tivozanib | 5% | 0% |
|
|